Elicera Therapeutics AB (publ) (ELIC.ST) Research

Elicera Therapeutics AB (publ), a Swedish immuno-oncology firm founded in Göteborg in 2014, is dedicated to the clinical development of cell and gene therapies that harness the immune system to combat cancer. Its promising pipeline features several drug candidates, including ELC-100, which is currently undergoing Phase I/II trials for neuroendocrine tumors. The company is also advancing ELC-201 and ELC-401 through preclinical development, with ELC-401 specifically targeting glioblastoma multiforme (a form of brain tumor). Furthermore, Elicera is developing ELC-301, a CAR T-cell therapy intended for the treatment of Non-Hodgkin's B-cell lymphoma. A cornerstone of their work is the iTANK technology platform, engineered to enhance the efficacy of their CAR T-cell therapies and stimulate killer T-cells to attack cancerous cells.

Market snapshot

Symbol
ELIC.ST
Price
$2.70
Day change
-7.55%
Market cap
$130.9M
P/E ratio
-9.29x
52-week range
2.255-8.43
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Acarix AB (publ) (ACARIX.ST)
  • Ascelia Pharma AB (publ) (ACE.ST)
  • Bio-Works Technologies AB (publ) (BIOWKS.ST)
  • Mendus AB (publ) (IMMU.ST)
  • Initiator Pharma A/S (INIT.ST)
  • Intervacc AB (publ) (IVACC.ST)
  • Karolinska Development AB (publ) (KDEV.ST)
  • Magle Chemoswed Holding AB (publ) (MAGLE.ST)

Open Elicera Therapeutics AB (publ) (ELIC.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.